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Background: The role of disulfide bond remodeling in HIV-1 infection is well described, but the process still
remains incompletely characterized. At present, the data have been predominantly obtained using established cell
lines and/or CXCR4-tropic laboratory-adapted virus strains. There is also ambiguity about which disulfide
isomerases/ reductases play a major role in HIV-1 entry, as protein disulfide isomerase (PDI) and/or thioredoxin (Trx)
have emerged as the two enzymes most often implicated in this process.
Results: We have extended our previous findings and those of others by focusing on CCR5-using HIV-1 strains and
their natural targets - primary human macrophages and CD4+ T lymphocytes. We found that the nonspecific thiol/
disulfide exchange inhibitor, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), significantly reduced HIV-1 entry and
infection in cell lines, human monocyte-derived macrophages (MDM), and also phytohemagglutinin (PHA)-
stimulated peripheral blood mononuclear cells (PBMC). Subsequent studies were performed using specific anti-PDI
or Trx monoclonal antibodies (mAb) in HIV-1 envelope pseudotyped and wild type (wt) virus infection systems.
Although human donor-to-donor variability was observed as expected, Trx appeared to play a greater role than PDI
in HIV-1 infection of MDM. In contrast, PDI, but not Trx, was predominantly involved in HIV-1 entry and infection of
the CD4+/CCR5+ T cell line, PM-1, and PHA-stimulated primary human T lymphocytes. Intriguingly, both PDI and Trx
were present on the surface of MDM, PM-1 and PHA-stimulated CD4+ T cells. However, considerably lower levels of
Trx were detected on freshly isolated CD4+ lymphocytes, compared to PHA-stimulated cells.
Conclusions: Our findings clearly demonstrate the role of thiol/disulfide exchange in HIV-1 entry in primary T
lymphocytes and MDM. They also establish a cell-type specificity regarding the involvement of particular disulfide
isomerases/reductases in this process and may provide an explanation for differences among previously published
studies. More importantly, from an in vivo perspective, the preferential utilization of PDI may be relevant to the
HIV-1 entry and establishment of virus reservoirs in resting CD4+ cells, while the elevated levels of Trx reported in
the chronic stages of HIV-1 infection may facilitate the virus entry in macrophages and help to sustain high viremia
during the decline of T lymphocytes.
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There have been an increasing number of studies sup-
porting an important role for thiol (−SH)/disulfide
(−S-S-) exchange in the entry of multiple viruses into
susceptible cells, including Sindbis virus [1] , Baculovirus
[2], Vaccinia virus [3], equine arteritis virus [4], Moloney* Correspondence: Kathleen.clouse@fda.hhs.gov
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reproduction in any medium, provided the ormurine leukemia virus [5], Newcastle disease virus [6-8],
hepatitis delta virus [9] and HIV-1 (reviewed in [10,11]).
HIV-1 entry requires attachment of the gp120 subunit
of the viral envelope (Env) glycoprotein to its primary
receptor, CD4. This interaction induces a structural re-
arrangement in Env, exposing conserved regions within
the gp120 subunit, thereby enabling binding to an ap-
propriate co-receptor, primarily the chemokine receptors
CXCR4 or CCR5 [12,13]. Engagement of gp120 to the
co-receptor triggers conformational changes in the gp41
subunit, exposing its hydrophobic amino-terminal fusionral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lowed by the formation of the six helix bundle (trimer-
of-hairpin) structure that enables fusion of the virus and
cell membranes and the subsequent release of the viral
capsid into the cytosol (reviewed in [12,14].
HIV-1 Env contains 10 disulfide bonds (nine in the
gp120 and one in the gp41 subunits, respectively)
[15], and the observed potent suppression of HIV-1
infection by disulfide isomerase inhibitors has
revealed the importance of thiol/disulfide exchange
during virus entry [16-21]. At present, there is still
ambiguity regarding which enzyme(s) mediate the di-
sulfide bond rearrangements. The majority of studies
investigating the effects of disulfide isomerase/reduc-
tase inhibitors [16-20,22], specific polyclonal and
monoclonal antibodies (Ab) directed against these
enzymes [16,18,20], as well as fluorescent microscopy
and Western blot analysis of gp120 interactions and/
or reduction of disulfide bonds [20,23,24], imply that
PDI is the key enzyme involved in the HIV-1 entry
process. However, it has also been reported [25] that
Trx plays a major role during HIV-1 Env induced fu-
sion, while PDI expression and/or function has a neg-
ligible effect. In yet another study [26], it was shown
that another member of the Trx superfamily,
glutaredoxin-1 (Grx1), can reduce disulfide bonds in
both CD4 and gp120, and its inhibition results in
reduced HIV-1 infection.
Thus, the significance of the thiol/disulfide exchange in
the process of HIV-1 infection has been established pre-
dominantly using CD4/coreceptor-positive cell lines and
laboratory-adapted, CXCR4-tropic (X4) HIV-1 strains,
with a limited number of studies employing primary
human cells and/or R5-tropic (R5) HIV-1 isolates
[16,19,22,25,26]. R5 strains of HIV-1 are primarily involved
in virus transmission; they predominate during the early
and asymptomatic stages of infection, and are typically
present throughout the symptomatic phase of HIV disease
(reviewed in [27]). For these reasons, we conducted a com-
prehensive study using a panel of distinct assays to focus
extensively on the significance of thiol/disulfide exchange
during entry of several R5-tropic HIV-1 strains, including
those that were minimally passaged, into their natural tar-
gets – primary human macrophages and CD4+ lympho-
cytes. In addition, we determined the effects of disulfide
reductase/isomerase inhibitors on human macrophage in-
fection with HIV-192UG024, one of the few primary X4-
tropic strains capable of infecting these cells [28]. Our
results provide critical new information on the role of di-
sulfide isomerases in HIV infection and further support
previous observations that thiol/disulfide exchange is
required for HIV-1 entry. More interestingly, our data re-
veal cell-type specificity with respect to the enzymes
involved in this process.Results
DTNB inhibits R5 Env pseudotyped virus infection in
CD4+/CCR5+ cell lines, primary macrophages and PBMCs
We initially examined the effect of the nonspecific thiol/
disulfide exchange inhibitor, DTNB, on the infection of
different cell types by luciferase (Luc) reporter gene-
encoding HIV-1JR-FL or HIV-1AD8 Env pseudotyped virus
particles. Since these particles were only competent for
single cycle infection and were produced using the same
backbone plasmid, their application allowed a more ac-
curate assessment of the effect of DTNB on distinct
HIV-1 Env-pseudotyped virions and/or experimental cell
systems. After a brief pre-incubation (~1 h), cells were
infected in the presence of DTNB for 2.5 h, followed
by an extensive washout of the reagent. About 48 h
later, cells were lysed, and Luc activity was measured
and expressed in relative light units (RLU). In HOS
CD4+/CCR5+ cells, DTNB exposure potently reduced
infection by HIV-1JR-FL or HIV-1AD8 Env-pseudotyped
virions (Figure 1A) without impairing cell viability (trypan
blue exclusion test). DTNB also caused a similar dose-
dependent suppression of HIV-1JR-FL Env-pseudotyped
virion infection of the JC53 CD4+/CCR5+ cell line, as well
as primary macrophages and PBMCs (Figure 1B,C,D),
without significantly altering the cell surface expression of
CD4 or chemokine co-receptors (data not shown). DTNB
incubation also has no effect on Luc activity in cells
directly electroporated with the pNL4-3 e-R+ Luc plasmid
used to generate the reporter gene-encoding HIV-1 Env
pseudotyped virus particles (data not shown), consistent
with previous observations that DTNB is nearly plasma
membrane impermeable [29,30].
DTNB inhibits HIV-1 particle fusion with primary human
cells and CD4+/CCR5+ cell lines
It is well-documented that the HIV-1 life cycle involves
multiple steps that include viral Env-mediated mem-
brane fusion, uncoating of viral RNA, reverse transcrip-
tion, proviral DNA integration, transcription, and
translation, as well as viral particle assembly and bud-
ding [31]. Given that DTNB could potentially interfere
with multiple cell surface proteins containing sulphydryl
groups, although unlikely, it was still possible that the ef-
fect of DTNB on HIV-1 replication could be nonspecific.
For this reason, we sought to examine the effect of
DTNB solely on virus entry by employing β-lactamase
(BlaM)-containing virions [32,33] prior to testing its ef-
fect on spreading HIV-1 infection in vitro. Negative con-
trols prepared for DTNB treated and untreated cells
confirmed that DTNB had no detrimental effects on
loading of the cells with the fluorescent dye, CCF2/AM,
and did not influence the background non-specific cell
fluorescence (Figure 2A, B, upper graphs). In addition,
cells electroporated with pMM310 (pcDNA3.1(Zeo)-
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Figure 1 The broad spectrum thio-isomerase inhibitor, DTNB, significantly reduces infection by HIV-1 Env pseudotyped virus particles.
The CD4+CCR5+ HOS (panel A,B) and JC53 (panel C) cell lines, as well as the primary human MDM (panel D) and PBMC (panel E) were pre-
incubated with different concentrations of DTNB for 1 h and then infected with HIV-1-Env pseudotyped virions in the presence of the inhibitor.
The infection was carried out for 2.5 h at 37°C in triplicate in a serum free medium. Cells were subsequently washed with DMEM and further
incubated in DM-10 for 48 h prior to lysis (0.5% Triton-100 in PBS) and measurement of Luc activity. Cell lysates from mock-infected cells and
from cells not treated with DTNB were used as a negative control and control, respectively. The P values for the differences between the control
and DTNB treated cells were calculated using the GraphPad Prism scientific software (t-test).
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loaded with the fluorescent dye CCF2/AM showed no
significant difference in the number of blue cells, com-
pared to cells incubated in DMEM only (data not
shown), indicating that DTNB did not affect the BlaM
enzymatic activity. Using HIV-1AD8 BlaM containing
virus particles, we established that DTNB significantly
inhibited fusion of HIV-1AD8 BlaM-containing virions
with both the JC53 CD4+/CCR5+ cell line (Figure 2A)
and primary human PBMCs (Figure 2B), as well as
MDMs (Figure 2C), indicating that its effect occurs pre-
dominantly at the level of virus entry and further sup-
porting the role for thiol/disulfide exchange in HIV-1
Env during infection.
Thiol/disulfide exchange is required for infection of
human MDM by primary HIV-1 strains
We next determined the effect of DTNB on wt infection
of human MDM by the laboratory adapted R5 strain,
HIV-1ADA, and the minimally passaged isolate, HIV-
1BCF03, as well as the primary X4 strain, HIV-192UG024.
DTNB was able to suppress infection by all three isolates
with levels of reverse transcriptase activity approaching
those observed for uninfected control MDM, indicating
that its effect was not strain specific (Figure 3A,B,C). Toidentify the disulfide reductases/isomerases involved in
HIV-1 infection of MDM and serving as potential tar-
gets for DTNB, the effects of specific monoclonal anti-
bodies (mAbs) against PDI and/or Trx, two enzymes
previously implicated in HIV-1 Env disulfude bond rear-
rangements [16-20] were evaluated. The mAbs were ap-
plied before and during virus adsorption/fusion; HIV-1
infection was monitored by measuring RT activity at
various time points throughout the course of infection.
Anti-PDI or anti-Trx mAbs significantly inhibited MDM
infection by all three HIV-1 strains tested. However, data
obtained from multiple experiments performed with
HIV-1ADA established that the anti-Trx mAb was more
efficient in reducing RT values and delaying the time of
peak RT activity during infection (Figure 3D,E and data
not shown), suggesting that Trx may play a greater role
in disulfide bond rearrangement in HIV-1 R5 isolates.
Anti-PDI, but not anti-Trx mAbs, suppressed HIV-1
infection in PM-1 T-cell line
We next investigated the role of PDI and/or Trx in virus
entry and infection of the T cell line, PM-1, which is
known to naturally express both CXCR4 and CCR5 and
can be infected with R5, as well as X4, HIV-1 strains.
We found that anti-PDI mAbs inhibited the infection of
Figure 2 DTNB inhibits fusion/entry of BlaM-containing virions in JC53 cells, primary human PBMCs and MDM. The BlaM-containing virus
particles were produced and the JC53 CD4+/CCR5+ cells, primary human MDM, and PBMCs were cultured as described in Methods. DTNB was
dissolved in pre-warmed phenol red free DMEM, and cells were pre-incubated for 1 h before addition of the virus. The infection period was 2 h
at 37°C in serum-free medium for the JC53 cells (panel A) and 2.5 h for the primary PBMCs (panel B) and MDM (panel C) in the presence of
DTNB. After incubation with BlaM-containing virus particles, cells were washed with DMEM, loaded with the fluorescent dye CCF2/AM for 1 h at
RT, washed and further incubated in DM-10 (phenol red free, supplemented with 2.5 mM Probenecid) for 14 h in tissue culture plates at RT in the
dark. Subsequently, the JC53 cells (after trypsinization) and the human PBMCs were transferred to microfuge tubes, fixed with 1.6%
pareformaldehyde and analyzed using BD LSR II Cell Fluorometer equipped with a violet laser (407 nm excitation wavelength) and 460/30 nm
and 530/20 nm emission filters for detection of the blue and green fluorescence, respectively (A,B). The primary human MDM (C), cultured in a
borosilicate glass bottom plate (Whatmann), were fixed in situ and analyzed using a Laser Scanning Cytometer (CompuCyte, Cambridge, MA).
Mock-infected cells (upper panels) were used to define the regions of negative (green) and positive (blue) cell populations in the presented
histograms. The experiment with human MDM was performed in triplicates. The infection of the JC53 cells and primary PBMC was carried out in
duplicate wells, which were combined before Flow Cytometry analysis.
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Figure 3 Inhibition of thiol-disulfide exchange suppresses HIV-1 infection of primary human MDM. After preincubation for 30 minutes.
with various concentrations of DTNB, anti-PDI or anti-Trx mAbs, MDM were infected (in duplicate, in the presence of the inhibitors) for 4 h with
the HIV-1 strains indicated, washed twice, and then maintained in MØ medium without the reagents. Cell culture supernatants were harvested
and replenished (80% v/v) every three days, and harvested supernatants were stored at −80°C before being analyzed for reverse transcriptase (RT)
activity.
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porter gene virus particles in a dose dependent manner
(Figure 4A). In contrast, the anti-Trx mAbs had no ef-
fect on the latter infection, even when used at a max-
imum concentration of 50 μg/ml. Similar results were
obtained when anti-PDI and/or anti-Trx treated PM-1
cells were infected with HIV-1NL4-3 Env pseudotyped
virions (data not shown). Furthermore, anti-PDI mAb,but not anti-Trx mAb, significantly reduced the RT
values and delayed the peak RT activity when PM-1 cells
were infected with the R5 laboratory-adapted strain,
HIV-1ADA, or the X4 strain, HIV-1LAV (Figure 4B,C).
Although affinity values for these mAbs could not be
obtained from their commercial sources, we established
Kd values for the anti-PDI and the anti-Trx mAbs of 15
nM and 8 nM, respectively using surface plasmon
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Figure 4 Anti-PDI, but not anti-Thioredoxin mAbs inhibit HIV-1 infection in PM-1 T-cell line. A. PM-1 cells were pre-incubated for 1 h in
RPMI-1640 containing the indicated concentrations of nonspecific mouse IgG, anti-PDI or anti-Trx mAbs prior to infection with HIV-1JR-FL Env
pseudotyped, Luc reporter gene-encoding virus particles for 2.5 h in the presence of the different mAbs. After the infection period, cells were
washed and further incubated for 48 h in RC-10 before being lysed with 0.5% Triton-X100 in PBS and Luc activity was measured. B, C. Following
preincubation for 30 minutes with 5 mM DTNB, anti-PDI or anti-Trx mAbs, PM-1cells were infected with HIV-1ADA (panel B) or HIV-1LAV (panel C).
After infection for 2 h in the presence of the aforementioned inhibitors, the PM-1 cells were washed and further incubated in RC-10 without
DTNB or mAbs. Cell culture supernatants were collected every two days and cryopreserved before being evaluated for RT activity.
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mAbs, as well as the length of incubation (0.5 -1 h pre-
incubation plus an additional 4 h during virus adsorp-
tion/infection), suggest comparable binding of the two
mAbs to their relevant targets, especially when used at
the highest concentration of 50 μg/ml (~330nM IgG).
Cell-type specific requirements for thiol/disulfide
exchange during HIV-1 entry and infection in primary
human peripheral blood lymphocytes (PBLs) and MDMs
Subsequent to our findings with PM-1 cells, primary
human PHA stimulated PBLs were infected with HIV-
1JR-FL Env-pseudotyped Luc reporter gene virus particles
in the presence and absence of the anti-PDI or anti-Trx
mAbs. As expected and consistent with our observationsusing the PM-1 T cell line, anti-PDI, but not the anti-
Trx mAb, reduced the Luc reporter gene activity in pri-
mary PBLs isolated from four different donors (Figure 5).
Primary MDM were evaluated for the effects of anti-PDI
or anti-Trx mAbs on HIV-1JR-FL Env-pseudotyped virus
infection using the same experimental system. In con-
trast to primary human PBLs, the anti-Trx mAb was
more effective at inhibiting HIV-1 infection of primary
MDM when present during the virus adsorption and
entry period. An opposite trend and statistically signifi-
cant differences (P≤0.01) were established between the
anti-PDI and anti-Trx treated cells for the PBL and
MDM systems, respectively (Figure 5). Given that the
mean Luc activity of the nonspecific IgG treated cells










































































Figure 5 Cell-Type Specific Requirements for Thioredoxin and/or PDI in HIV-1 Infection in Primary Human Cells. PHA stimulated PBL
were pre-incubated for 1 h with relevant mAbs (50 μg/ml) and then infected for 2.5 h with HIV-1JR-FL Env pseudotyped, Luc reporter gene
encoding virus particles in the continued presence of the mAbs. After infection, the cells were washed and further incubated for 48 h in RPMI
supplemented with 10% FCS and L-Glutamine prior to lysis (0.5% Triton-X100 in PBS) and Luc activity was then measured. MDM were treated and
infected in an identical manner, using DMEM medium. The amount of HIV-1 Env pseudotyped virus particles was adjusted according to the
number of cells subjected to infection. Primary human MDM or PBLs from four different donors were prepared and tested as described in
Methods. The RLU established for the anti-PDI or anti-Trx mAbs treated cells were calculated as a percent of the mean Luc activity of cells pre-
incubated and infected in the presence of nonspecific mouse IgG. The means of the four established values from each donor for the anti-PDI or
anti-Trx mAbs treated PBL and MDM are presented in the left and right panel of Figure 5, respectively.
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ferences between the control and anti-PDI or control
and anti-Trx treated cells in Figure 5. However, the dif-
ferences between the control and anti-PDI treated PBL
and between the control and anti-Trx treated MDM
were found to be statistically significant for all donors
tested when primary data (RLU) were used to calculate
the relevant P values (P≤0.05, not shown).
PDI and Trx are expressed the cell surface of PM-1 T cells,
primary MDM and PBLs
In an attempt to delineate the basis for the observed
cell-type specific requirements of the thiol/disulfide ex-
change during virus entry, cell surface expression of PDI
and Trx was assessed in the various cell types used for
infection. The same mAb clones used to inhibit HIV-1
infection were directly conjugated to different fluores-
cent dyes (anti-PDI- DyLight 488 and anti-Trx-APC),
and used for Flow Cytometry analysis. Although PDI
and Trx are predominantly found as intracellular pro-
teins, it is well-documented that these molecules can
also be secreted and associate with the plasma mem-
brane [34-36]. Given that cell surface PDI and Trxmolecules are peripheral plasma membrane proteins, the
cells prepared for Flow Cytometry analysis of cell surface
PDI and Trx were washed with DPBS, fixed with 1.6%
paraformaldehyde prior to labeling to prevent dissoci-
ation from the cell surface and then treated with NH4Cl
to quench the reactive aldehyde groups before incuba-
tion with the specific mAbs as described in Methods. In
addition to the anti-PDI and anti-Trx mAbs, PBLs
were also incubated with a specific anti-CD4 mAb,
directly labeled with the fluorescent marker, Pacific
blue, and only those cells that stained positive for
CD4 were further analyzed for their PDI and Trx
cell surface levels. We found that PM-1 cells and
primary MDM expressed both PDI and Trx on their
surface (Figure 6A,B). Intriguingly, in contrast to
PDI which was present to comparable levels on both
unstimulated and PHA-activated CD4+ T cells, Trx
expression was very low on unstimulated CD4+ lym-
phocytes, but increased significantly after PHA treat-
ment (Figure 6C). Taken together our findings
strongly suggest that the cell type specific effects of
anti-PDI and anti-Trx mAbs observed in PM-1 cells,
primary MDM, and PHA activated PBLs cannot be
Figure 6 (See legend on next page.)
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Figure 6 Cell surface expression of PDI and/or Thioredoxin. PM-1 T cells (panel A), primary human MDM (panel B) and PBLs (panel C) were
isolated and cultured as described in Methods. Subsequently, the cells were fixed with 1.6% paraformaldehyde and treated with NH4Cl to quench
the reactive aldehyde groups before labeling. The PDI and Trx levels on the cell surface were detected by a combination of directly labeled anti-
PDI-FITC and anti-Trx-APC mAbs from the same clones used in the HIV-1 infection experiments. In addition, the unstimulated and PHA-P
stimulated PBLs were labeled with anti-CD4-Pacific blue conjugated mAb, and the PDI and Trx expression were analyzed on the CD4+
lymphocyte (Ly) population. The results were analyzed and the final graphs were created using FlowJoe software.
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plasma membrane of the various cells that have been
tested.
Discussion
There is growing evidence that thiol/disulfide exchange
is required for the complex conformational changes that
occur during virus-cell fusion. The mature HIV-1 Env is
expressed as a trimer of gp120-gp41 heterodimers on
the surface of virions and/or infected cells. HIV-1 gp120
consists of five variable domains (V1-V5) interconnected
by five more conserved regions (C1-C5), delineated by
nine intra-chain disulfide bonds [37,38]. The gp41 ecto-
domain, in addition to its hydrophobic N-terminus,
encompasses two hydrophobic regions with a character-
istic coiled-coil structure, designated as heptad repeats 1
and 2, that are connected by a linker sequence forming a
conserved disulfide bond [12,39,40]. Although there have
been published reports from several independent studies
on this topic, the number, location and timing of the
HIV-1 Env disulfide bond modifications during virus
entry are still not completely elucidated. The majority of
disulfide bonds in gp120, delineating or inside domains
V1/V2 (Cys126-Cys196; Cys119-Cys205; Cys131-Cys157), V3
(Cys296-Cys331), V4 (Cys385-Cys418), C1 (Cys54-Cys74), C2
(Cys218-Cys247) and C4 (Cys378-Cys445), as well as the di-
sulfide bond in gp41, have all been implicated as po-
tential targets for reduction and/or isomerization
[11,19,41-43]. There has been some ambiguity with re-
spect to when the disulfide bond rearrangements in
gp120 take place: immediately following CD4-gp120
binding [19,20] or after the interaction of gp120 with
CD4 and the relevant coreceptor [17,44]. It is reason-
able to suggest that some of the disulfide bonds could
be modified right after CD4 binding, if such rearrange-
ments facilitate the subsequent coreceptor association
while others, such as the disulfide bond straddling the
V3 loop and critical for the integrity of the coreceptor
binding site [15,45], may undergo modification after
the gp120-CD4-coreceptor complex is formed.
It has also been reported that the disulfide bond in the
second immunoglobulin-like domain (D2) of CD4 under-
goes redox changes necessary for HIV-1 entry but, similar
to the situation with HIV-1 Env, the precise timing and role
of the CD4 redox modifications during the process of virus
fusion remain incompletely characterized [41,46,47]. Atpresent, there is no consensus regarding the particular di-
sulfide reductases/isomerases that may be required for
HIV-1 infection. Experimental data from various studies
have confirmed the PDI mediated disulfide bond rearrange-
ments in both gp120 [11,20,23,24] and CD4 [26], as well as
the suppression of HIV-1 infection by PDI inhibitors
[16-20]. However, Trx has also been shown to induce redox
changes in gp120 [25,42] and CD4 [25,46] and Ou et al.,
[25] found that Trx, not PDI, played a major role in HIV-1
Env-mediated fusion. Interestingly, it was recently reported
[43] that, despite certain quantitative differences, PDI and
Trx generally target the same disulfide bonds within gp120.
Auwerx et al., [26] established that another oxidoreductase,
Grx1, in addition to PDI, caused a disulfide bond reduction
in gp120 and CD4 and also observed a significant (~50%),
but incomplete, inhibition of HIV-1RW009 infection by poly-
clonal anti-Grx1 Abs.
Given that there have been only a few reports on the
effects of disulfide reductase/isomerase inhibitors on
HIV-1 infection of primary human cells [16,19,26], our
current study set out to provide a comprehensive inves-
tigation of the role of thiol/disulfide exchange in HIV-1
infection using primary human PBMCs, PBLs and
MDMs. Using single cycle as well as multi-round repli-
cation assays, we initially tested the effects of the non-
specific disulfide isomerase/reductase inhibitor, DTNB,
employing predominantly R5 strains. In contrast to
other viruses, such as hantaviruses [30] where surface
glycoproteins express free thiol groups, it is unlikely that
DTNB will interact directly with the HIV-1 Env, since
those cysteines are interlinked via disulfide bonds. How-
ever, if reductase activity is not completely suppressed
during the virus-cell fusion process, especially when
lower DTNB concentrations are applied, potential alkyl-
ation by DTNB of the newly generated thiol groups may
contribute to its inhibitory activity. We established that
DTNB potently reduced HIV-1 entry and infection in
primary cells to levels comparable to the observed inhib-
ition in cell lines (Figure 1 and 2). DTNB also inhibited
MDM infection by all strains tested, including the pri-
mary, minimally passaged R5 strain BCF03 and X4 strain
UG024. Attempts to identify the particular disulfide
reductases/isomerases involved in HIV-1 entry by apply-
ing specific mAbs, unexpectedly revealed a clearly distin-
guished specificity among the various cell types tested
(Figure 4 and 5). In MDM, anti-Trx mAbs proved to be
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HIV-1 entry and infection. In contrast, these same anti-
Trx mAbs had negligible effects on the PM-1 T cell line
and primary PBLs, while the anti-PDI mAbs significantly
reduced HIV-1 infection in these cells (Figure 3, 4 and
5). Intriguingly, both PDI and Trx were present on the
plasma membrane of all cell types tested (Figure 6). Al-
though it appeared that MDMs displayed higher levels
of Trx than PDI on their surface, it is unlikely that this
fact alone could account for the differences in the HIV-1
inhibitory activities of the anti-Trx and anti-PDI mAbs.
In support of this notion, PM-1 cells and PHA stimu-
lated PBLs expressed comparable levels of Trx and PDI
on their surface, while anti-PDI and anti-Trx mAbs
clearly exerted distinct patterns on HIV-1 infection
when compared to each other or to their effects on pri-
mary human MDM (Figure 4 and 5). It was previously
shown that gp120, CD4, CXCR4 and PDI co-localize on
the cell surface [20] and we speculated that a preferen-
tial temporal association of gp120, CD4 and the relevant
corecepor with either PDI or Trx might be the reason
for the observed cell-type specific oxidoreductase in-
volvement in HIV-1 entry. Molecular docking analysis
revealed that PDI may interact with the third
immunoglobulin-like (D3) region of CD4 [10]. D3 con-
tains one of the glycosylation sites in human CD4 [48]
and it is conceivable that subtle differences in CD4 gly-
cosylation may result in its preferential interaction with
PDI in some cell types, but not in others. CD4 is also
known to interact with the tyrosine kinase p56lck in
PBLs and T cell lines, but not in monocytes and MDM
[49], which may also influence its behavior on the cell
surface in a cell-type dependent manner. CCR5 and
CXCR4 heterogeneity [50], as well as their preferential
cell type dependent interactions with CD4 [45], may also
be contributing factors to the cell-type specific disulfide
reductase/isomerase involvement in HIV-1 entry. Alter-
natively, or in combination with the parameters already
discussed, there may be differences in the way T lym-
phocytes/T cell lines and macrophages regulate the bal-
ance between the oxidized and reduced forms of PDI
and/or Trx on their surface, which in turn may favor the
preferential involvement of one of these enzymes during
HIV-1 entry. Cell surface molecules other than CD4 and
CCR5 may also interact with PDI or Trx and influence
their redox status and/or availability during HIV-1 entry.
It was recently reported [51] that galectin-9 binds to and
increases the retention of PDI on the cell surface, thus
facilitating Th2 lymphocyte migration and HIV-1 infec-
tion most likely through modulation of the cell surface
redox environment.
There is evidence that, in addition to PDI and Trx,
there may be other disulfide reductases like Grx1 [26]
participating in the HIV-1 Env-mediated fusion.Whether these alternative disulfide reductases/iso-
merases display cell-type specific activities remains to be
established. Interestingly, both PDI (Figure 5) and Grx1
[26] significantly, but incompletely (~50%) reduced
HIV-1 infection in PBLs and/or PBMCs, suggesting
that certain oxidoreductases may substitute for each
other during HIV-1 entry.
Finally, we looked at our results from the perspective
of HIV-1 infection in vivo in an attempt to better under-
stand HIV-1 pathogenesis. The redox imbalance is a
hallmark of HIV-1 infection, resulting in a complex
chain of events at intra- and extracellular levels that in-
fluence HIV-1 replication (reviewed in [52,53]). The
finding that freshly isolated PBLs, in contrast to PHA-
stimulated cells, express ample amounts of PDI yet ex-
press relatively low levels of Trx on their surface, may
provide insights regarding the predominant utilization of
PDI by CD4+ lymphocytes, the entry of HIV-1 in resting
T cells, and the establishment of virus reservoirs. Given
that MDM utilize predominantly Trx during HIV-1
entry (Figures 3D,E and 5), the observed elevation of
plasma Trx during chronic stages of HIV disease [54,55]
may enhance macrophage infection and help sustain
high viremia even when very low levels of CD4+ T-cells
exist. In this regard, plasma Trx levels showed a signifi-
cant inverse correlation with the survival rate of HIV-1-
infected patients having a CD4+ T cell count below 200
cells/μL [55].
The enormous potential of HIV-1 to mutate [56], its
ability to establish long-lasting viral reservoirs that are
currently impossible to completely eradicate even with
the highly active anti-retroviral therapy (HAART) [57],
along with the emergence of resistant strains to the
CCR5 antagonist maraviroc (Selzentry) (reviewed in
[58]) and/or the fusion inhibitor T-20 (Enfuvirtide) [59],
emphasize the importance of developing new and effect-
ive therapies to suppress virus entry. Therefore, the
identification of more conserved host cellular factors,
such as the disulfide reductases/ isomerases involved in
HIV-1 pathogenesis, and our increased understanding of
their mechanisms of action, may facilitate the future de-
velopment of new antiviral modalities.
Conclusions
Our findings clearly establish the role of thiol/disulfide ex-
change in HIV-1 entry and infection of primary T cells and
MDM by a variety of strains, including isolates that have
been minimally passaged. Regarding the involvement of
particular disulfide isomerases/reductases in this process,
our results also demonstrate a cell-type dependent specifi-
city and may provide an explanation for differences among
previously published studies. From an in vivo perspective,
the preferential utilization of PDI may be relevant to the
HIV-1 entry and establishment of virus reservoirs in resting
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chronic stages of HIV-1 infection may facilitate the virus
entry in macrophages and help to sustain high viremia dur-
ing the decline of T lymphocytes.
Methods
Reagents
5,5`-dithiobis[2-nitrobenzoic acid] (DTNB) was purchased
from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum
(FBS) was obtained from Hyclone (Logan, UT). Phosphate
Buffered Saline (PBS) and RPMI 1640 medium were pur-
chased from Lonza (Walkersville, MD). Phenol red-free
Dulbecco’s Modified Eagle’s Medium (DMEM), HEPES
buffer solution (1 M) and the CCF2/AM β-lactamase Load-
ing Kit (GeneBLAzer Reporter Assay) were purchased from
Invitrogen Corp. (Carlsbad, CA). Penicillin/Streptomycin
antibiotic solution (10,000U/ml and 10,000 μg/ml, respect-
ively), sodium pyruvate (100 mM), Dulbecco’s Phosphate
Buffered Saline (DPBS) and L-glutamine (200 mM) were
obtained from Lonza (Walkersville, MD). The Luciferase
Assay System and the FuGENE 6 transfection reagent were
purchased from Promega Corp. (Madison, WI) and Roche
Applied Science (Indianapolis, IN), respectively.
The HIV-1ADA virus stock was purchased from
Advanced Biotechnologies (Columbia, MD). HIV-1BCF03
[60] and HIV-192UG024 (the UNAIDS Network for HIV
Isolation and Characterization and DAIDS, NIAID) were
received through the AIDS Research and Reference Re-
agent Program, NIAID, NIH.
The plasmids pNL4-3 e-R+ Luc, pSV7d-JR-FLgp160,
pSV7d-AD8gp160 and pMM310 (pcDNA3.1(Zeo)-Vpr-
BlaM) were provided by Dr. R. Doms (Univ. Penn.), Dr.
G. Quinnan (USUHS, Bethesda, MD), and Dr. M. Miller
(Merck & Co., Inc., West Point, PA), respectively.
Mouse monoclonal anti-PDI antibody (mAb), clone 1D3,
and polyclonal rabbit anti-PDI antibody (pAb) were pur-
chased from Enzo Life Sciences (formerly Stressgen and
Assay Designs) (Ann Arbor, MI). The mouse anti-human
Trx mAb, clone 2B1, was obtained from AbD Serotec (Ra-
leigh, NC). Unlabeled, Pacific Blue, FITC or PE-Cy5 conju-
gated isotype IgG controls, anti-human CD4 (clone Leu3a),
anti-human CCR5 (clone CTC5), anti-human CXCR-4
(clone 12 G5) and goat anti-mouse F(ab)2–AlexaFluor 488
were purchased from eBiosciences (San Diego, CA), BD
Biosciences (San Jose, CA) and Life Technologies (Grand
Island, NY). Human FcR blocking reagent was purchased
from Miltenyi Biotec (Auburn, CA) and the LYNX Rapid
APC Antibody Conjugation kit was obtained fron AbD
Serotec.
Cells and cell culture conditions
The 293 T, JC53 [61], HOS CD4+/CCR5+ and PM-1 cell
lines were obtained from Dr. G. Quinnan (USUHS,
Bethesda, MD), Dr. D. Dimitrov (NCI, Frederick), theAIDS Research and Reference Reagent Program, NIAID,
NIH: Dr. M. Reitz [62], and the American Type Culture
Collection (ATCC), respectively. The cell lines were
maintained in DMEM (293 T, JC53 and HOS) or RPMI-
1640 (PM-1), supplemented with 10% FCS, 2 mM L-glu-
tamine, and antibiotics (DM-10 or RC-10) at 37°C in a
humidified, 5% CO2 atmosphere. Human PBMC were
isolated by Ficoll-PaqueTM gradient centrifugation from
leukapheresis of healthy, human donors seronegative for
HIV-1, HIV-2, hepatitis B and hepatitis C. Monocytes
and lymphocytes were further separated using counter-
current centrifugal cell elutriation as previously
described [63]. For the Luc reporter gene and the BlaM
entry assays, macrophages were prepared from elutriated
monocytes by differentiation in 100 mm square Petri
dishes (Bibbi Sterilin Ltd., Stone Staffs, UK) in DMEM
supplemented with 10% human serum pooled from mul-
tiple normal donors, 2 mM L-glutamine and antibiotics
(MØ medium) [64,65]. Human MDM were obtained
after 7 to 14 days of differentiation in the absence of ex-
ogenous growth factors and were either used immedi-
ately after the differentiation period or kept frozen in
liquid nitrogen. The day before the experiment, frozen
cells were thawed, washed, centrifuged, and resuspended
in DM-10 medium prior to incubation at 37°C overnight.
For the wild type (wt) HIV-1 infection experiments,
monocytes were differentiated for 7 days in 6-well tissue
culture plates (Costar; MA), harvested and re-plated into
24-well plates (Nunc, Roskilde, Denmark) 24 to 48 h
prior to HIV-1 infection (0.75 x 106 cells/well in 1.5 mL
of medium). PBL were either kept frozen or used imme-
diately after elutriation. After stimulation for 72 h with
PHA-P 10 μg/ml (Sigma-Aldrich, St. Louis, MO), PBL
were washed, counted and infected with HIV-1 Env
pseudotyped or HIV-1 BlaM-containing virions in 24
well plates (106 cells/well).
Surface plasmon resonance analysis
The experiments were performed using a Biacore T200
system (GE Healthcare). The two mAbs tested were
immobilized on CM5 sensors either directly (anti-Trx)
or indirectly (anti-PDI) via anti-mouse Fc rabbit IgG
(Jackson Immunoresearch Laboratories, West Grove,
PA). Both the anti-Trx mAb and the rabbit anti-mouse
Fc IgG were cross-linked to the CM5 sensors using an
amine coupling kit (GE Healthcare). Human recombin-
ant Trx and PDI were obtained from Sigma-Aldrich
(St. Louis, MO) and Enzo Life Sciences (Farmingdale,
NY), respectively, and the binding to their relevant
mAbs was tested over a concentration range of 12.5 to
400 nM. After each cycle, the surfaces of the CM5 sen-
sors were regenerated by applying low pH glycine buf-
fer, as the efficiency of the regeneration procedures
were verified in prior pilot experiments. The generated
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for kinetic analysis.
Flow cytometry
CD4 and PDI were detected using the directly conju-
gated mAbs anti-CD4 (clone Leu3a)-Pacific Blue (BD
Pharmingen) and anti-PDI (clone 1D3)-DyLight 488
(Assay Designs), respectively. Relevant isotype controls
were obtained from the same companies. The anti-Trx
mAb, clone 2B1, (AbD Serotec) and relevant isotype
control IgG were labeled with the fluorescent dye APC
using the LYNX Rapid APC Antibody Conjugation kit,
following the manufacturer’s instructions (AbD Serotec).
The non-overlapping emission and excitation spectra of
Pacific blue, DyLight 488 and APC allowed simultaneous
labeling with the three different mAbs and subsequent
Flow Cytometry analysis with minimal interference. The
PM-1 cells and the primary human lymphocytes were
washed with DPBS (x1), fixed in 1.6% paraformaldehyde,
washed again with DPBS (x1) and incubated for 30 min
in 10 mM NH4Cl to quench the free aldehyde groups
and reduce unspecific antibody binding. Primary MDM
were treated identically after detachment from plastic by
washing and incubation with DPBS (Ca2+ and Mg2+ free)
at 4°C, followed by pipetting and gentle scraping, if ne-
cessary. Cells were further washed (x1) in DPBS and
incubated overnight in DPBS plus 3% bovine serum al-
bumin (BSA). Subsequently, the cells were labeled simul-
taneously with the anti-CD4, anti-PDI, and anti-Trx
mAbs or the relevant isotype controls (1 h at 4°C in
DPBS, 3% BSA, 2.5 μg of each of the mAbs per 106
cells), washed 3 times with DPBS and analyzed using the
LSR II BD Cell Analyzer. For detection of CCR5 and/or
CXCR4, cells were initially labeled with the relevant
antibodies on ice and subsequently fixed in 1.6% parafor-
maldehyde before Flow Cytometry analysis. CCR5 and
CXR4 were detected either by using PE-Cy5 conjugated
specific antibodies (BD Biosciences) or using non-
conjugated anti-CXCR4 (clone 12 G5) and anti-CCR5
(clone 2D7) mAbs, followed by goat anti-mouse FITC-
conjugated IgG F(ab)2, (Life Technologies, NY).
Infection studies using HIV-1 Env pseudotyped virus
particles
For the reporter gene HIV-1-Env pseudotyping system
[66], viral stocks were prepared by transfecting 293 T
cells with plasmids encoding the Luc virus backbone
pNL4-3-Luc e-R+ and pSV7d-JR-FLgp160 or pSV7d-
AD8gp160. After transfection, the cells were washed ex-
tensively with DMEM and further incubated for 24–48 h.
The resulting supernatants were clarified by centrifuga-
tion for 10 min at 1500 rpm, filtered through low protein
binding 45 μM syringe filters (Millipore, Bedford, MA)
and used immediately or kept at 4°C for up to 48 h.CD4/coreceptor positive cells were prepared in 96
(50x103 cells/well) or 48 well (1.5x105 cells/well) plates
and infected with 25 or 50 μl virus suspension per well,
respectively. No DEAE-Dextran or polybrene were used
to facilitate fusion. DTNB, anti-PDI or anti-Trx mAbs
(in serum free DMEM) were applied as indicated in the
figure legends. After the 2.5 h period for virus infection
(in a serum free medium), the cells were extensively
washed and then incubated for 48 h (in medium sup-
plemented with 10% FBS) prior to lysis with 0.5%
Triton-100 in PBS (Luc reporter gene studies). A 50 μl
aliquot of the resulting lysate was assayed for Luc activity
using the appropriate substrate (Promega, Madison, WI).
To exclude the possibility of DTNB having an effect on
Luc expression at a post-entry level, HOS cells were elec-
troporated with the pNL4-3 e-R+ plasmid, incubated for
3.5 h on the next day in concentrations of DTNB used in
the virus infection experiments and lysed and tested for
Luc activity 48 h later. The statistical analysis of the
experiments employing HIV-1 Env pseudotyped, Luc re-
porter gene encoding virus particles was performed using
the GraphPad Prism scientific software (t-test).
HIV-1 entry assay
BlaM-containing virus particles were produced by
co-transfection of 293 T cells with a plasmid encoding
HIV-1AD8 proviral DNA and pMM310. The pMM310
construct encodes BlaM fused to the amino-terminus of
the viral protein Vpr, which directs BlaM into the form-
ing virions [33,67]. After pre-incubation and infection
for 2.5 h (in a serum free medium), the cells were exten-
sively washed and loaded with the fluorescent dye
CCF2/AM (2 μM final concentration) for 1 h, washed to
remove the extracellular dye and incubated in phenol
red free DMEM plus 10% FCS, 2 mM L-Glutamine and
25 mM HEPES in the presence of the nonspecific anion
transport inhibitor, probenecid (2.5 mM), for 12–14 h
prior to fixing with 1.6% paraformaldehyde [32]. The ex-
tent of CCF2/AM cleavage by the virus-introduced
intracellular BlaM, detected by the change in dye emis-
sion from the green to the blue spectrum, was evaluated
by measuring the fluorescence using Laser Scanning
Cytometer (CompuCyte, Cambridge, MA) or BD LSR II
Cell Analyzer generating light at 407 nm and equipped
with HQ460/30 and HQ530/20 filters for detection of
the blue and green emission, respectively. Individual
negative controls (mock infection) were prepared for
both medium- or DTNB-treated cells to define more
precisely the region of BlaM positive cells in the Laser
Scanning or Flow Cytometry experiments. To exclude
the possibility of DTNB having an effect on BlaM activ-
ity, HOS and/or JC53 cells were electroporated with the
parental (pCDNA3.1) or the Vpr-BlaM encoding plas-
mid, incubated for 3.5 h on the next day in 5 mM
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AM and analyzed by Flow Cytometry as described for
the virus entry experiments.HIV-1 infection of human MDM and PM-1 cells
24–48 h after being seeded in a 24 well plate, the macro-
phages were washed, incubated 30 min with different disul-
fide reductase/isomerase inhibitors or the appropriate
controls, and infected for 4 h with select HIV-1 strains in
the presence of the reagents. Subsequently, the cells were
washed and further incubated in MØ medium without di-
sulfide reductase inhibitors. The progression of virus repli-
cation was monitored by measuring reverse transcriptase
(RT) activity as follows: every 3rd day, ~80% of the culture
medium was harvested and replaced, with the collected
medium stored at −80°C until evaluation.
Following preincubation for 30 minutes with 5 mM
DTNB, anti-PDI or anti-Trx mAbs, PM-1 cells were
infected with HIV-1ADA (panel B) or HIV-1LAV (panel C) in
24 well plates. After infection for 2 h in the presence of the
aforementioned inhibitors, the PM-1 cells were washed and
further incubated in RC-10 without DTNB or mAbs. Cell
culture supernatants were collected every two days and
cryopreserved before being evaluated for RT activity. The
RT assay employed in the current study was a 3H-based
modification of the methods described by Hoffman et al.
[68]. For both MDM and PM-1 cells the values shown re-
flect the average of duplicate samples (cpm/25 μl) that dif-
fered by not more than 15%.
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